Factors Predicting Microinvasion in Ductal Carcinoma in situ

  • Ozkan-Gurdal, Sibel ;
  • Cabioglu, Neslihan ;
  • Ozcinar, Beyza ;
  • Muslumanoglu, Mahmut ;
  • Ozmen, Vahit ;
  • Kecer, Mustafa ;
  • Yavuz, Ekrem ;
  • Igci, Abdullah
  • Published : 2014.01.15


Background: Whether sentinel lymph node biopsy (SLNB) should be performed in patients with pure ductal carcinoma in situ (DCIS) of the breast has been a question of debate over the last decade. The aim of this study was to identify factors associated with microinvasive disease and determine the criteria for performing SLNB in patients with DCIS. Materials and Methods: 125 patients with DCIS who underwent surgery between January 2000 and December 2008 were reviewed to identify factors associated with DCIS and DCIS with microinvasion (DCISM). Results: 88 patients (70.4%) had pure DCIS and 37 (29.6%) had DCISM. Among 33 DCIS patients who underwent SLNB, one patient (3.3%) was found to have isolated tumor cells in her biopsy, whereas 1 of 14 (37.8%) patients with DCISM had micrometastasis (7.1%). Similarly, of 16 patients (18.2%) with pure DCIS and axillary lymph node dissection (ALND) without SLNB, none had lymph node metastasis. Furthermore, of 20 patients with DCISM and ALND, only one (5%) had metastasis. In multivariate analysis, the presence of comedo necrosis [relative risk (RR)=4.1, 95% confidence interval (CI)=1.6-10.6, P=0.004], and hormone receptor (ER or PR) negativity (RR=4.0, 95%CI=1.5-11, P=0.007), were found to be significantly associated with microinvasion. Conclusions: Our findings suggest patients presenting with a preoperative diagnosis of DCIS associated with comedo necrosis or hormone receptor negativity are more likely to have a microinvasive component in definitive pathology following surgery, and should be considered for SLNB procedure along with patients who will undergo mastectomy due to DCIS.


Ductal carcinoma in situ;sentinel lymph node biopsy;microinvasion


  1. Intra M, Rotmensz N, Veronesi P, et al (2008). Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast. Ann Surg, 247, 315-9.
  2. Zavagno G, Belardinelli V, Marconato R, et al(2007). Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion. Breast, 16, 146-51.
  3. Houghton J, George WD, Cuzick J (2003). Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet, 362, 95-102.
  4. Greenlee RT, Hill-Harmon MB, Murray T, et al (2001). Cancer statistics 2001. CA Cancer J Clin, 51, 15-36.
  5. Ikeda DM, Andersson I (1989). Ductal carcinoma in situ: atypical mammographic appearances. Radiology, 172, 661-6.
  6. Intra M, Zurrida S, Maffini F, et al (2003). Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol, 10, 1160-5.
  7. Katz A, Gage I, Evans S, et al (2006).Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg, 191, 761-6.
  8. Wilkie C, White L, Dupont E, et al (2005). An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg, 190, 563-6.
  9. Winchester DP, Menck HR, Osteen RT, et al (1995). Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol, 2, 207-13.
  10. Yen TW, Hunt KK, Ross MI, et al (2005). Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg, 200, 516-26.
  11. Yu KD, Wu LM, Liu GY, et al (2011). Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol, 18, 1342-8.
  12. Cutuli B, Cohen-Solal-Le Nir C, De Lafontan B, et al (2001). Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer, 37, 2365-72.
  13. Baxter NN, Virnig BA, Durham SB, et al (2004). Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst, 96, 443-8.
  14. Boyages J, Delaney G, Taylor R (1999). Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer, 85, 616-28.<616::AID-CNCR12>3.0.CO;2-7
  15. Cavaliere A, Scheibel M, Bellezza G, et al (2006). Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profile. Pathol Res Pract, 202, 131-5.
  16. Adlard JW, Bundred NJ (2006). Radiotherapy for ductal carcinoma in situ. Clin Oncol, 18, 179-84.
  17. Altintas S, Lambein K, Huizing MT, et al (2009). Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J, 15, 120-32.
  18. Daly MB (2006). Tamoxifen in ductal carcinoma in situ. Semin Oncol, 33, 647-9.
  19. Dershaw DD, Abramson A, Kinne DW (1989). Ductal carcinoma in situ: mammographic findings and clinical implications. Radiology, 170, 411-5.
  20. Edge SB, Byrd DR, Compton CC, et al (2009). AJCC Cancer Staging Handbook, seventh edition. Chicago: Springer, pp419-60.
  21. Ernster VL, Barclay J, Kerlikowske K, et al (1996). Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA, 275, 913-8.
  22. Fisher B, Dignam J, Wolmark N, et al (1998). Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from national surgical adjuvant breast and bowel project B-17. J Clin Oncol, 16, 441-52.
  23. Silverstein MJ, Lagios MD, Groshen S, et al (1999). The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med, 340, 1455-61.
  24. Sakr R, Barranger E, Antoine M, et al (2006). Ductal carcinoma in situ: value of sentinel lymph node biopsy. J Surg Oncol, 94, 426-30.
  25. Silver SA, Tavassoli FA (1998). Mammary ductal carcinoma in situ with microinvasion. Cancer, 82, 2382-90.<2382::AID-CNCR12>3.0.CO;2-L
  26. Silverstein MJ (2003). The University of Southern California/ Van Nuys prognostic index for DCIS of the breast. Am J Surg, 186, 337-43.
  27. Silverstein M, Skinner K, Lomis T (2001). Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg, 25, 767-72.
  28. Silverstein MJ, Waisman JR, Gamagani P, et al (1990). Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment of choice. Cancer, 66, 102-8.<102::AID-CNCR2820660119>3.0.CO;2-5
  29. Skinner KA, Silverstein MJ (2001). The management of ductal carcinoma in situ of the breast. Endocr Relat Cancer, 8, 33-45.
  30. Tan JC, McCready DR, Easson AM, et al (2007). Role of sentinel lymph node biopsy in ductal carcinoma in-situ treated by mastectomy. Ann Surg Oncol, 14, 638-45.
  31. Vieira CC, Mercado CL, Cangiarella JF, et al (2010). Microinvasive ductal carcinoma in situ: Clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol, 73, 102-7.
  32. Wei Z, Er-li G, Yi-li Z, et al (2012). Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer. World J Surg Oncol, 10, 262.
  33. Anderson B (2000). Axillary metastases with DCIS: is the glass half empty or half full? Ann Surg Oncol, 7, 631-3.
  34. Ozmen V, Karanlik H, Cabioglu N, et al (2006). Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat, 95, 1-6.
  35. Lagios MD, Margolin FR, Westdahl PR, et al (1989). Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer, 63, 618-24.<618::AID-CNCR2820630403>3.0.CO;2-J
  36. Mabry H, Giuliano AE, Silverstein MJ (2006). What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg, 192, 455-7.
  37. Mirza NQ, Vlastos G, Meric F, et al (2000). Ductal carcinoma in situ: long term results of breast-conserving therapy. Ann Surg Oncol, 7, 656-64.
  38. Park SY, Lee HE, Li H, et al (2010). Heterogeneity for stem cellrelated markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res, 16, 876-87.
  39. Roses RE, Paulson C, Sharma A, et al (2009). HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev, 18, 1386-9.
  40. Rosner D, Bedwani RN, Vana J, et al (1980). Noninvasive breast carcinoma: results of a national survey by the American College of surgeons. Ann Surg, 192, 139-47.

Cited by

  1. Relation of Alcohol/Tobacco use with Metastasis, Hormonal (Estrogen and Progesterone) Receptor Status and c-erbB2 Protein in Mammary Ductal Carcinoma vol.15, pp.14, 2014,
  2. Systemic Analysis on Risk Factors for Breast Cancer Related Lymphedema vol.15, pp.16, 2014,
  3. US-guided 14G Core Needle Biopsy: Comparison Between Underestimated and Correctly Diagnosed Breast Cancers vol.15, pp.7, 2014,
  4. Sentinel lymph node biopsy in patients with breast ductal carcinoma in�situ: Chinese experiences pp.1792-1082, 2015,
  5. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ vol.167, pp.3, 2018,
  6. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion vol.97, pp.44, 2018,
  7. Clinicopathologic analysis of a large series of microinvasive breast cancers vol.24, pp.4, 2018,
  8. Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy pp.1880-4233, 2018,
  9. Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion vol.98, pp.1, 2019,
  10. N-Acetylglucosaminyltransferase III (GnT-III) but not N-Acetylgalactosaminyltransferase-6 and 8 are Differentially Expressed in Invasive and In Situ Ductal Carcinoma of the Breast pp.1532-2807, 2019,